Compositions and methods for the treatment and prevention of lens fibrotic diseases
Compositions and methods for treating fibrotic diseases are provided.
1. A method of inhibiting lens fibrotic disease, said method comprising administering to the eye of a patient in need thereof a therapeutically effective amount of at least one skeletal muscle stem cell targeting molecule and at least one cytotoxic molecule,
wherein said at least one skeletal muscle stem cell targeting molecule is conjugated to said at least one cytotoxic molecule,
wherein said skeletal muscle stem cell is present in the lens, and
wherein said skeletal muscle stem cell targeting molecule is an antibody immunologically specific for a molecule selected from the group consisting of G8 antigen, syndecans, c-Met, CD34, and M-cadherin.
2. The method of claim 1 , wherein said at least one skeletal muscle stem cell targeting molecule and at least one cytotoxic molecule are contained within a composition further comprising at least one pharmaceutically acceptable carrier.
3. The method of claim 1 , wherein said lens fibrotic disease is posterior capsular opacification or anterior subcapsular opacification.
4. The method of claim 1 , wherein said cytotoxic molecule is selected from group consisting of complement, heat sensitive carbon nanocrystals, cytotoxic antibiotics, cationic amphipathic lytic peptides, radionuclides, and toxins.
5. The method of claim 1 , wherein said skeletal muscle stem cell targeting molecule and said cytotoxic molecule is administered directly to the lens or the surrounding tissue.
6. The method of claim 1 , wherein said skeletal muscle stem cell targeting molecule is a G8 antibody.
7. The method of claim 4 , wherein said cytotoxic molecule is complement.
8. The method of claim 1 , wherein said skeletal muscle stem cell targeting molecule is an antibody which specifically binds a molecule selected from the group consisting of G8 antigen, syndecans, and c-Met.
9. The method of claim 1 , wherein said at least one skeletal muscle stem cell targeting molecule and at least one cytotoxic molecule are administered intraocularly.
10. The method of claim 1 , wherein said syndecans is syndecan-3 or syndecan-4.
11. The method for claim 1 , wherein said skeletal muscle stem cell targeting molecule is an antibody immunologically specific for a molecule selected from the group consisting of syndecan-3, syndecan-4, and c-Met.